Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 4/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737709 | 1.00 | FABP7 (0.55) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL10119919 | 0.95 | ALDH1A1 (0.50) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL6736507 | 0.95 | ALDH1A1 (0.50) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL10119915 | 0.92 | FABP7 (0.51) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL6737480 | 0.92 | FABP7 (0.51) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL10119916 | 0.92 | FABP7 (0.51) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL13688299 | 0.92 | FABP7 (0.51) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL6737702 | 0.92 | FABP7 (0.51) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL14827600 | 0.87 | FABP7 (0.53) | FABP7FABP5ALDH1A1HTTGLA | |
| SCHEMBL14827601 | 0.87 | FABP7 (0.53) | FABP7FABP5ALDH1A1HTTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100152438-A1 | AMPHIPHILIC MOLECULAR MODULES AND CONSTRUCTS BASED THEREON | COVALENT PARTNERS LLC | 2010-06-17 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7563890-B2 | Amphiphilic molecular modules and constructs based thereon | COVALENT PARTNERS, LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152438-A1 | AMPHIPHILIC MOLECULAR MODULES AND CONSTRUCTS BASED THEREON | ANXA6, THEM6, ANXA5 | FABP7 90/4885FABP5 126/4885ALDH1A1 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.